The efficacy and safety of intravenous (i.v.) and subcutaneous recombinant @entity1 @entity1307 (rh-EPO, @entity1307 ) for the treatment of @entity417 is well established. Subcutaneous administration of @entity1307 is recommended by current guidelines because it is more flexible and convenient than i.v. dosing, enables dose reduction of @entity1307 and results in cost benefits. Subcutaneous administration of @entity1307 beta permits flexible dosing regimens that can be tailored to @entity1 ' individual needs. This was demonstrated in a recent, large, randomized, controlled trial in which once-weekly dosing of @entity1307 beta was as effective as the same total dose administered two or three times weekly. New developments in delivery devices for self-administration, which are more convenient and acceptable to @entity1 , also contribute to the ability to individualize treatment. Furthermore, educating @entity1 in the management of @entity417 encourages collaboration between @entity1 and health care providers, enabling more tailored treatment regimens to be developed. In conclusion, the use of flexible dosing frequencies, easy-to-use delivery devices and @entity1 education may increase @entity1 compliance and encourage self-administration of @entity1307 beta. The ability to individualize @entity1307 beta therapy increases the number of options available to nephrologists and their @entity1 , leading to greater opportunities to tailor treatment according to specific needs.

A rationale for an individualized administration frequency of XXXX beta: a clinical perspective.

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient'] @entity417 :: ('MESH:D000740', 'Disease') :: ['renal anaemia'] @entity1307 :: ('2056', 'Gene') :: ['erythropoietin', 'epoetin']
@entity1307 :: (2056,Gene) :: ['epoetin']
